President Cancer Care Centers of South Texas
Hematology
Dr. Roger M. Lyons, MD
|
|
Give Review
Roger M. Lyons, MD works in the field of Hematology. He over the years received 6 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Meaningful Use Stage 1 Certification", "Top MD" and "Super Doctor". Roger M. Lyons, MD is a published physician as well. He has 34 publications published. The latest was: Comparing different routes and doses of phytonadione for reversing excessive anticoagulation.
Publications
- Three-year efficacy, oVerall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
- Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic Syndromes in a prospective registry.
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
- Long-term treatment with romiplostim in patients with Chronic immune thrombocytopenia: safety and efficacy.
- Myelodysplastic Syndromes: therapy and outlook.
- Oral ezatiostat HCl (Telintra(R), TLK199) and Idiopathic Chronic Neutropenia (ICN): A case report of complete response of a patient with G-CSF resistant ICN following...
- A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic Leukemia.
- Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated Acute myelogenous leukemia.
- Phase II study of clofarabine monotherapy in previously untreated older adults with Acute myeloid leukemia and unfavorable prognostic factors.
- Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic Syndrome and thrombocytopenia.
- Clinical roundtable monograph. Choosing an appropriate therapy for lower-risk MDS in the community setting.
- Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic Syndromes.
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with Chronic ITP.
- Recent advances in low- and intermediate-1-risk myelodysplastic Syndrome: developing a consensus for optimal therapy.
- AMG 531, a thrombopoiesis-stimulating protein, for Chronic ITP.
- Low-dose vitamin K to augment antiCoagulation control.
- Initial management of Immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care.
- Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes.
- Sustained expression of therapeutic levels of human factor VIII in mice.
- Gamma heavy chain Disease: rapid, sustained response to cyclophosphamide and prednisone.
- Membrane changes associated with platelet activation. Exposure of actin on the platelet surface after thrombin-induced secretion.
- Development of chronic myelocytic leukemia during the course of Acute lymphocytic leukemia in an adult.
- Efficacy and safety of enoxaparin to prevent Deep venous thrombosis after hip replacement surgery. Enoxaparin Clinical Trial Group.
- Comparing different routes and doses of phytonadione for reversing excessive antiCoagulation.
- The incidence and impact of thrombocytopenia in myelodysplastic Syndromes.
- Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent Lymphoma.
- Controversies in antithrombotic therapy for patients with mechanical heart valves.
- Improved quality of life for romiplostim-treated patients with Chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.
- Secondary prevention of Venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
- Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic Syndromes.
- Efficacy of romiplostim in patients with Chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Schools
University Of Manitoba Faculty Of Medicine
Winnipeg Genl Hospital
Barnes Wohl Hosps
Washington University
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
- Top MD
- Super Doctor
Education
-
Washington University - Barnes-Jewish Hospital -
University of Manitoba
Drug Facts
| NPI NUMBER | 1508838285 | |
| NPPES Provider LastName | LYONS | |
| NPPES Provider FirstName | ROGER | |
| NPPES Provider ZIPCode | 782293822 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology | |
| Total Claim Count | 1044.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 105.0 | |
| Percent Opioid Claims | 10.06 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508838285 |
| Last Name Of The Provider | LYONS |
| First Name Of The Provider | ROGER |
| View All |
Similar Doctors
|
|
Dr. Edgar A. Castillo Dandreis, MD |
|
Dr. Behyar Zoghi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles H. Mims Jr., MD |
|
|
Dr. Raetasha S. Dabney, MD |
|
|
Dr. Sukeshi R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carl R. Meier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar Freytes, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Francis J. Giles, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joel D. Bessman, MD
This Doctor is OpenDoctor Recommended.
|